Swiss precision delivery device maker medmix AG slashed its annual dividend by 80% after full-year revenue fell 7.4% to CHF 448 million, missing expectations and prompting a cautious 2026 outlook. The Baar-based company proposed a dividend of CHF 0.10 per share for 2025, down from CHF 0.50 the prior year, as it adopted a performance-driven dividend policy with a minimum payout of 40% of earnings per share.

Drug Delivery revenue collapsed 19.6% organically to CHF 34.2 million, while Beauty dropped 12.9% to CHF 152.1 million. Dental was the lone bright spot in Healthcare, growing 5.9% organically to CHF 120.1 million. Despite the revenue decline, net income swung to CHF 7 million from a loss of CHF 6.4 million in 2024, driven by higher gross profit and lower expenses.

Adjusted EBITDA came in at CHF 89.7 million with a 20% margin, above the company's guidance range and up 90 basis points year on year. For 2026, medmix guided for flat to low single-digit organic revenue growth and maintained its medium-term revenue compound annual growth rate target of above 4%. Chief Executive René Willi said the company had "significantly improved our margin and profitability despite lower revenues" as shares tumbled 17%.